The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

Gadducci, Angiolo; Tana, Roberta; Cosio, Stefania; Genazzani, Andrea Riccardo

doi:10.1016/j.critrevonc.2007.09.002

Cited by 138 publications

(149 citation statements)

References 92 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…FDG-PET has shown high sensitivity in the detection of different types of cancer in many studies (8)(9)(10)(11)(15)(16)(17). A similar high sensitivity was obtained in our study.…”

Section: Fold Increase In Tumor Markerssupporting

confidence: 77%

“…Many investigations have shown that FDG-PET is capable of detecting metastases and locally recurrent disease in many types of cancer, including breast, ovarian, colorectal and cervical cancer, using asymptomatically elevated tumor markers. In this regard, it is superior to conventional imaging modalities such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), radiography and bone scintigraphy (8)(9)(10)(11). However, few studies have evaluated the efficacy of FDG-PET for cancer detection in patients with elevated blood tumor markers but without a history of malignancy, and those that have been conducted comprised a small number of patients (12,13).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Application of FDG-PET for detection of malignant lesions in patients with elevated blood tumor markers but without a history of malignancy

Zhan

Xu²,

Ye³

et al. 2009

Mol Med Rep

View full text Add to dashboard Cite

Abstract. The aim of this study was to evaluate the clinical application of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging for the detection of malignant lesions. A total of 132 patients with increased levels of blood tumor markers but without a prior history of malignancy were examined. The results of FDG-PET and conventional work-up (CWU) including computed tomography (CT), ultrasonography, radionuclide bone scintigraphy and endoscopy were compared. The final diagnosis was based on pathological evidence, other medical imaging results and a follow-up of at least 6 months. There were 61 patients with malignant lesions and 71 without (benign lesions, n=35; healthy individuals, n=36). The average number of elevated tumor markers and the average increase in these tumor markers were greater in the malignant group than in the non-malignant group. FDG-PET imaging revealed that the maximum standardized uptake value (SUVmax) of the major lesion in patients with malignant (n=61) and benign (n=35) tumors was not significantly related to increased levels of tumor markers (r=0.10, p<0.05). In patients with malignant lesions and an SUVmax ≥3.0, the diagnostic sensitivity, specificity, accuracy, positive predictive value and negative predictive value of FDG-PET were 95.1, 83.1, 88.6, 82.9 and 95.2%, respectively. CWU identified 61 (100%) true-positive patients. No statistically significant differences in sensitivity were observed between the results of FDG-PET and CWU (p>0.05). In 36 healthy subjects without abnormal CWU findings, no abnormal FDG accumulation was revealed by FDG-PET imaging. In conclusion, FDG-PET imaging is a valuable tool for the detection of malignant lesions in patients with increased levels of blood tumor markers but without a history of malignancy. It is therefore reasonable to apply FDG-PET imaging in situations in which the results of CWU are inconclusive, or when patients wish to limit the number of examinations they must undergo.

show abstract

“…FDG-PET has shown high sensitivity in the detection of different types of cancer in many studies (8)(9)(10)(11)(15)(16)(17). A similar high sensitivity was obtained in our study.…”

Section: Fold Increase In Tumor Markerssupporting

confidence: 77%

Section: Introductionmentioning

confidence: 99%

Application of FDG-PET for detection of malignant lesions in patients with elevated blood tumor markers but without a history of malignancy

Zhan

Xu²,

Ye³

et al. 2009

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…21 However, the clinical relevance of these tumor-associated antigens is still debated. 22 Because to our knowledge there is no validated tumor marker, 5 there is an urgent need to identify new biomarkers for the early detection and management of patients with cervical cancer. CT antigens are predominantly expressed in normal gametogenic tissues as well as in different histologic types of tumors, and therefore they represent ideal diagnostic and therapeutic candidates.…”

Section: Discussionmentioning

confidence: 99%

Sperm‐associated antigen 9 is a biomarker for early cervical carcinoma

Garg

Kanojia

Salhan

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

“…It is detected in the exo-and endocervix in CC [7]. Elevated CA-125 was reported in 43-75% of women with adenocarcinoma and in 19-26% of women with squamous cell carcinoma (SCC) of the cervix [8][9][10]. Moreover, some studies have shown that the complementary evaluation covering CA-125 and SCC antigen (SCC-Ag) in serum is one of the prognostic factors related to the number of positive LNs and survival in SCC [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Preoperative measurement of serum CA-125 levels: is it useful in the risk assessment of low volume lymph node disease in cervical cancer?

Śniadecki

Wojtylak

Wycinka

et al. 2017

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

Cited by 138 publications

References 92 publications

Application of FDG-PET for detection of malignant lesions in patients with elevated blood tumor markers but without a history of malignancy

Application of FDG-PET for detection of malignant lesions in patients with elevated blood tumor markers but without a history of malignancy

Sperm‐associated antigen 9 is a biomarker for early cervical carcinoma

Preoperative measurement of serum CA-125 levels: is it useful in the risk assessment of low volume lymph node disease in cervical cancer?

Contact Info

Product

Resources

About